Abstract 440P
Background
Targeted therapy is emerging as the frontline of cancer treatment due to improved clinical outcomes and enhanced quality of life among cancer patients. However, treatments related to adverse events (AEs) of targeted therapy are associated with the outcome of cancer treatments. This study investigated the frequency and severity of adverse events in cancer patients who receive targeted therapy.
Methods
The study was conducted at a university hospital in northern Thailand, from January to June 2023. We performed a retrospective study concerning patients treated with targeted therapy including multikinase inhibitors, epidermal-growth factors (EGFR) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, cyclin-dependent kinases 4 and 6 (CDK4/6), immune checkpoint inhibitors (ICIs), mammalian target of rapamycin (mTOR) inhibitors, and phosphoinositide 3-kinases (PI3Ks) inhibitors. All adverse events were reported by pharmacists and confirmed by medical oncologists in electronic medical record (EMR) based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Descriptive statistics were applied for reporting frequency of AEs.
Results
There are 136 cancer patients with targeted therapy. The majority of patients were female (58.1%) with mean age 64.0 ± 11.9 years old. Non-small cell lung cancer is the most common cancer (47.1%) followed by hepatocellular carcinoma (14.7%) and breast cancer (11%). The frequency of targeted therapy treatment was erlotinib (18.4%), ceritinib (18.4%), regorafenib (10.3%) and ribociclib (8.1%). Eighty-two patients (60.3%) reported AEs. The most AEs were grade 1-2 (64%). Skin rash was the most common AE (22.8%), subsequently with dry skin (16.9%) and diarrhea (14.7%). Six patients (4.4%) had grade 3 AEs including skin rash (0.7%), Hand foot skin reaction (0.7%), transaminitis (1.5%), and neutropenia (1.5%).
Conclusions
This study demonstrated the frequency of AEs among cancer patients with targeted therapy, the most common AEs included dermatological problems. Rarely severe AEs were reported. Health care providers will need to educate and monitor cancer patients to prevent and monuments AEs during targeted therapy treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract